The PiggyBac DNA Modification System is the core technology we use in the development of our CAR-T therapies. PiggyBac efficiently delivers a large amount of genetic cargo into T cells to create therapies with many desirable features not present in earlier-generation CAR-T therapies.
Today, the majority of CAR-T therapies are produced using viral-based manufacturing, which can present inherent challenges including concerns around patient safety, limited genetic cargo capacity, and an more mature phenotype of the final product. Instead of using viral vectors to create our therapies, the non-viral piggyBac platform delivers CAR molecule genes to T cells. The most significant advantage of this approach is its ability to generate CAR-T products with a high percentage of TSCM cells.
We believe this will result in therapies that elicit more consistent and durable responses, with less toxicity. Additionally, our non-viral approach has apparent lower manufacturing costs and shortened manufacturing timelines when compared to earlier-generation products. In short, the non-viral piggyBac DNA Modification System allows us to produce what we believe to be better CAR-T therapies.